It is currently unclear whether an S1PR1,R5 modulator can produce a sustained reduction of autoantibodies in SLE patients and whether this reduction is require to achieve therapeutic benefits on kidney function. The gene discussed is S1PR1; the disease is systemic lupus erythematosus.